Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Treat-to-target or treat-to-dissolve strategy to improve gout treatment

Nature Reviews Rheumatology (2024)Cite this article

Subjects

Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stamp, L. K. et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 4, E53–E60 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. O’Dell, J. R. et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. https://doi.org/10.1056/evidoa2100028 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Russell, M. D. et al. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. Lancet Reg. Health Eur. 18, 100416 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380–390 (2020).

    Article  PubMed  Google Scholar 

  5. Hammer, H. B. et al. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Ann. Rheum. Dis. 79, 1500–1505 (2020).

    Article  PubMed  Google Scholar 

  6. Ives, A. et al. Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. Nat. Commun. 6, 6555 (2015).

    Article  CAS  PubMed  Google Scholar 

  7. Perez-Ruiz, F., Herrero-Beites, A. M. & Carmona, L. A two-stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis. Arthritis Rheum. 63, 4002–4006 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Cipolletta, E. et al. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328, 440–450 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Doherty, M. et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403–1412 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cipolletta, E., Abhishek, A., Di Battista, J., Grassi, W. & Filippucci, E. Ultrasonography in the prediction of gout flares: a 12-month prospective observational study. Rheumatology (Oxford) 62, 1108–1116 (2023).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, INSERM U1132, Lariboisière Hospital, Université Paris-Cité, Paris, France

    Pascal Richette

  2. Department of Medicine, University of Auckland, Auckland, New Zealand

    Nicola Dalbeth

Authors
  1. Pascal Richette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Dalbeth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pascal Richette.

Ethics declarations

Competing interests

P.R. received fees from Horizon. N.D. received fees from AstraZeneca, Novartis, Horizon, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, Dexcel Pharma, Shanton Pharma and Avalo outside the submitted work.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Richette, P., Dalbeth, N. Treat-to-target or treat-to-dissolve strategy to improve gout treatment. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01117-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41584-024-01117-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing